Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 20.01%
- Healthy long term growth as Net Sales has grown by an annual rate of 27.91%
- Company has very low debt and has enough cash to service the debt requirements
2
Flat results in Dec 24
3
With ROE of 1.91%, it has a Very Expensive valuation with a 1.05 Price to Book Value
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
HKD 24,511 Million ()
55.00
NA
4.08%
-0.17
1.83%
0.93
Revenue and Profits:
Net Sales:
1,544 Million
(Quarterly Results - Dec 2013)
Net Profit:
-502 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.03%
0%
-10.03%
6 Months
-14.26%
0%
-14.26%
1 Year
7.74%
0%
7.74%
2 Years
-26.32%
0%
-26.32%
3 Years
-54.86%
0%
-54.86%
4 Years
-51.91%
0%
-51.91%
5 Years
-63.06%
0%
-63.06%
Shandong Weigao Group Medical Polymer Co. Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
27.91%
EBIT Growth (5y)
23.38%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.16
Sales to Capital Employed (avg)
0.20
Tax Ratio
33.01%
Dividend Payout Ratio
47.66%
Pledged Shares
0
Institutional Holding
0.01%
ROCE (avg)
15.45%
ROE (avg)
20.01%
Valuation key factors
Factor
Value
P/E Ratio
55
Industry P/E
Price to Book Value
1.05
EV to EBIT
17.14
EV to EBITDA
14.53
EV to Capital Employed
1.06
EV to Sales
3.87
PEG Ratio
NA
Dividend Yield
3.68%
ROCE (Latest)
6.18%
ROE (Latest)
1.91%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'13 - YoY
Dec'13
Dec'12
Change(%)
Net Sales
1,544.20
1,029.30
50.02%
Operating Profit (PBDIT) excl Other Income
370.70
251.20
47.57%
Interest
2.20
4.10
-46.34%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-501.80
285.60
-275.70%
Operating Profit Margin (Excl OI)
195.30%
203.10%
-0.78%
USD in Million.
Net Sales
YoY Growth in quarter ended Dec 2013 is 50.02% vs -1.52% in Dec 2012
Consolidated Net Profit
YoY Growth in quarter ended Dec 2013 is -275.70% vs -91.66% in Dec 2012
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
14,189.30
14,618.50
-2.94%
Operating Profit (PBDIT) excl Other Income
3,593.50
3,497.80
2.74%
Interest
270.60
301.60
-10.28%
Exceptional Items
29.20
-10.20
386.27%
Consolidate Net Profit
2,344.90
2,278.10
2.93%
Operating Profit Margin (Excl OI)
179.40%
170.80%
0.86%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -2.94% vs -8.56% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 2.93% vs -33.60% in Dec 2023
About Shandong Weigao Group Medical Polymer Co. Ltd. 
Shandong Weigao Group Medical Polymer Co. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






